Development of Real-Time Surveillance for Serious Adverse Events in a Pragmatic Clinical Trial Using National Registers in Finland

dc.contributor.authorNieminen, Tuomo A.
dc.contributor.authorPalmu, Arto A.
dc.contributor.authorAuvinen, Raija
dc.contributor.authorKulathinal, Sangita
dc.contributor.authorAuranen, Kari
dc.contributor.authorSyrjänen, Ritva K.
dc.contributor.authorNieminen, Heta
dc.contributor.authorMoore, Tamala Mallett
dc.contributor.authorPepin, Stephanie
dc.contributor.authorJokinen, Jukka
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organizationfi=tilastotiede|en=Statistics|
dc.contributor.organization-code1.2.246.10.2458963.20.42133013740
dc.converis.publication-id478101651
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/478101651
dc.date.accessioned2025-08-27T22:44:10Z
dc.date.available2025-08-27T22:44:10Z
dc.description.abstract<p>Purpose: We developed a hybrid safety surveillance approach for a large, pragmatic clinical trial of a high-dose quadrivalent influenza vaccine (QIV-HD), using both active and passive data collection methods. Here, we present the methods and results for the passive register-based surveillance of serious adverse events (SAEs), which replaced conventional SAE reporting during the trial. <br></p><p>Patients and Methods: The trial recruited over 33,000 older adults of whom 50% received the QIV-HD while the rest received a standard-dose vaccine (QIV-SD) as a control vaccine. We collected diagnoses related to all acute hospitalizations during the six months following vaccination from national registers. During the blinded phase of the trial, we utilized a cohort study design and compared the incidences of 1811 ICD10 diagnosis groups (SAE categories) between the trial population and older adults vaccinated with the QIV-SD outside the trial, either during the study or the previous influenza season. Based on a real-time probabilistic comparison, we flagged SAE categories with higher incidence in the trial population and then evaluated possible causal associations between each flagged category and the trial intervention. <br></p><p>Results: Our novel approach to safety surveillance provided information, which we could evaluate in real-time during the trial. The trial participants experienced 1217 hospitalizations related to any SAE categories, contributed by 941 patients. We flagged 10 SAE categories for further analysis during the study but based on further data review, none presented strong evidence of causality with vaccination. <br></p><p>Conclusion: Safety signals can be detected and evaluated in real-time during a pragmatic vaccine trial with register-based follow-up, utilizing passive data collection and population level comparison. Compared to conventional methods of safety follow-up, this method is likely to be more comprehensive, objective and resource effective.</p>
dc.format.pagerange901
dc.format.pagerange915
dc.identifier.eissn1179-1349
dc.identifier.olddbid202707
dc.identifier.oldhandle10024/185734
dc.identifier.urihttps://www.utupub.fi/handle/11111/48528
dc.identifier.urlhttps://doi.org/10.2147/CLEP.S483034
dc.identifier.urnURN:NBN:fi-fe2025082789875
dc.language.isoen
dc.okm.affiliatedauthorAuranen, Kari
dc.okm.affiliatedauthorDataimport, Kliinisen laitoksen yhteiset
dc.okm.discipline112 Statistics and probabilityen_GB
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline112 Tilastotiedefi_FI
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherDOVE MEDICAL PRESS LTD
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.publisher.placeALBANY
dc.relation.doi10.2147/CLEP.S483034
dc.relation.ispartofjournalClinical Epidemiology
dc.relation.volume16
dc.source.identifierhttps://www.utupub.fi/handle/10024/185734
dc.titleDevelopment of Real-Time Surveillance for Serious Adverse Events in a Pragmatic Clinical Trial Using National Registers in Finland
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
CLEP-483034-development-of-real-time-surveillance-for-serious-adverse-ev.pdf
Size:
1.25 MB
Format:
Adobe Portable Document Format